Indole and indazole compounds as an inhibitor of cellular necrosis

1. An indole compound of the following formula (1):

in which

n denotes a number of 1 to 3,

m denotes 0 or 1,

A represents phenyl,

X represents C or CH, with the proviso that m is 1 when X is C,

R 1 represent hydrogen, alkyl, —(CH 2 ) r NR 7 R 8 , or —(CH 2 ) r CO 2 H, wherein r denotes a number of 1 to 5, and R 7 and R 8 independently of one another represent hydrogen, alkyl or alkylcarbonyl, or may together form an optionally alkyl-substituted alkylene chain wherein optionally one methylene is replaced by N atom,

R 2 represents hydrogen, halogen, cyano, nitro, hydroxy, alkyl, alkoxy or trialkylsilyl, represents —(CH 2 ) p CO 2 R 7 , —(CH 2 ) p OR 7 , —(CH 2 ) p NR 7 R 8 , —NHR 10 , —N(H)S(O) 2 R 7 , —NHC(O)R 10 , —(CH 2 ) p S(O) 2 R 7 or (CH 2 ) p -heterocycle-R 10 , wherein p denotes a number of 0 to 3, R 7 and R 8 are as defined above, R 10 represents hydrogen, oxo, alkylsulfonyl, alkylcarbonyl, alkyloxycarbonyl, alkylaminocarbonyl, alkoxy, alkyl or heterocycle,

R 3 represents hydrogen, cyano, halogen, alkyl or phenyl, or represents —(CH 2 ) n -heterocycle or —(CH 2 ) n -aryl, wherein n denotes a number of 0 to 3,

R 4 represents —YR 11 , wherein Y represents a direct bond or —(CR 7 R 8 ) p Y′—, wherein p denotes a number of 0 to 3, R 7 and R 8 are as defined above, Y′ is selected from the group consisting of —O—, —S—, —NR 12 —, —NR 12 C(O)—, —C(O)—, —C(O)O—, —C(O)NR 12 —, —S(O) q —, and —S(O) q NR 12 —, wherein R 12 represents hydrogen, alkyl, aryl or heteroaryl, q denotes a number of 0 to 2, R 11 is selected from the group consisting of hydrogen, cyano, halogen, hydroxy, thiol, carboxy, alkyl and —(CH 2 ) t B—R 13 , wherein t denotes a number of 0 to 3, B represents heterocycle, heteroaryl or aryl, R 13 represents hydrogen, cyano, halogen, hydroxy, oxo, thiol, carboxy, carboxyalkyl, alkylcarbonyloxy, alkyl, alkoxy, alkylthio, alkylcarbonyl or alkylsulfonyl,

R 5 represents hydrogen, alkyl, cycloalkyl, heterocycle or heterocyclylalkyl,

R 6 represents —(CR 7 R 8 ) p —Z-D-W—R 14 , wherein Z represents a direct bond, or is selected from the group consisting of —C(O)—, —C(O)O—, —C(O)NR 12 —, and —S(O) y —, y denotes a number of 1 or 2, D represents a direct bond, or represents cycloalkyl, heteroaryl or heterocycle, W represents a direct bond, or represents —NR 7 —, —C(O)—, —C(O)O—, —C(O)NR 12 —, —S(O) y —, —S(O) y NR 12 — or —NR 12 S(O) y —, wherein R 14 represents hydrogen, hydroxy, alkyl, alkoxy, heterocycle, heteroaryl, aryl or aralkyl,

R 5 and R 6 together represent alkylene chain,

where alkyl, alkoxy, aryl, cycloalkyl, heterocycle and heteroaryl may be optionally substituted, and the substituents are one or more selected from the group consisting of hydroxy, halogen, nitrile, amino, alkylamino, dialkylamino, carboxy, alkyl, alkoxy, carboxyalkyl, alkylcarbonyloxy, alkylthio, alkyloxycarbonyl, alkylaminocarbonyl, arylalkoxy and oxo,

provided that R 3 is phenyl when X is CH, and

provided that R 6 is not hydrogen when X is C,

or a pharmaceutically acceptable salt or a stereoisomer or geometric isomer thereof.

2. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 1 wherein

n denotes a number of 1 to 3,

m denotes 0 or 1,

A represents phenyl,

X represents C or CH, with the proviso that m is 1 when X is C,

R 1 represents hydrogen, C 1 -C 6 -alkyl or —(CH 2 ) r NR 7 R 8 , wherein r denotes a number of 2 to 3, and R 7 and R 8 independently of one another represent hydrogen or C 1 -C 3 -alkyl, or may together form C 2 -C 6 -alkylene chain which is optionally substituted by C 1 -C 6 -alkyl and optionally one methylene is replaced by N atom,

R 2 represents hydrogen, halogen, C 1 -C 6 -alkyl, —(CH 2 ) p CO 2 R 7 , —(CH 2 ) p OR 7 , —(CH 2 ) p NR 7 R 8 , —NHR 10 , —N(H)S(O) 2 R 7 , —NHC(O)R 10 , —(CH 2 ) p S(O) 2 R 7 or —(CH 2 ) p -heterocycle-R 10 ,

p denotes a number of 0 to 3,

R 10 represents hydrogen, oxo, C 1 -C 6 -alkylsulfonyl, C 1 -C 6 -alkylcarbonyl, C 1 -C 6 -alkyloxycarbonyl, C 1 -C 6 -alkylaminocarbonyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl or hydroxy-C 1 -C 6 -alkyl, or represents 5-6 membered heterocycle which has 1 or 2 nitrogen atoms as the hetero atom, and is optionally substituted by C 1 -C 3 -alkyl,

R 3 represents hydrogen, halogen or C 1 -C 6 -alkyl, represents phenyl optionally substituted by C 1 -C 6 -alkoxy, or represents heterocyclyl-C 1 -C 5 -alkyl wherein the heterocycle is 5-6 membered, has 1 or 2 hetero atoms selected from N and O, and is optionally substituted by 1 or 2 oxo groups, provided that R 3 is phenyl when X is CH,

R 4 represents —YR 11 , wherein Y represents a direct bond or —(CR 7 R 8 ) p Y′—, wherein Y′ is selected from the group consisting of —O—, —C(O)—, —C(O)O—, —NHC(O)—, —NR 12 —, —C(O)NR 12 —, —S(O) q —, and —S(O) q NR 12 —, R 12 represents hydrogen or C 1 -C 3 -alkyl, q denotes a number of 0 to 2,

R 11 is selected from the group consisting of hydrogen, halogen, hydroxy, thiol, carboxy, C 1 -C 6 -alkyl, hydroxy-C 1 -C 6 -alkyl and —(CH 2 ) 1 B-R 13 , t denotes a number of 0 to 3, B represents C 6 -C 10 -aryl, represents 5-6 membered heterocycle having 1 or 2 hetero atoms selected from N, O and S, or represents 5-6 membered heteroaryl having 1 or 2 N atoms, R 13 represents hydrogen, halogen, hydroxy, oxo, thiol, carboxy, carboxy-C 1 -C 6 -alkyl, C 1 -C 6 -alkylcarbonyloxy, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkylthio, C 1 -C 6 -halogenoalkyl, C 1 -C 6 -alkylcarbonyl or C 1 -C 6 -alkylsulfonyl,

R 5 represents hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, heterocycle or heterocyclyl-C 1 -C 6 -alkyl, wherein the heterocycle is a 3-8 membered ring which has 1 to 3 hetero atoms selected from N and O, and is optionally substituted by 1 or 2 oxo groups,

R 6 represents —(CR 7 R 8 ) p —Z-D-W—R 14 ,

Z represents a direct bond, or is selected from the group consisting of —C(O)—, —C(O)O—, —C(O)NR 12 —, and —S(O) y —, wherein y denotes a number of 1 to 2,

D represents C 4 -C 6 -cycloalkyl, or represents 5˜6 membered heterocycle which has 1 or 2 hetero atoms selected from N, O and S, and optionally contains an oxo group,

W represents a direct bond, or represents —NR 7 —, —C(O)—, —C(O)O—, —C(O)NR 12 —, —S(O) y —, —S(O) y NR 12 — or —NR 12 S(O) y —,

R 14 represents hydrogen, hydroxy, C 1 -C 6 -alkyl, hydroxy-C 1 -C 6 -alkyl, carboxy-C 1 -C 6 -alkyl, C 6 -C 10 -aryl or C 6 -C 10 -ar-C 1 -C 6 -alkyl, represents 5-6 membered heterocycle which has 1 to 3 hetero atoms selected from N, O and S, and is optionally substituted by 1 or 2 oxo groups, or represents 5-6 membered heteroaryl which has 1 to 3 hetero atoms selected from N, O and S, and is optionally substituted by C 1 -C 6 -alkyl, or

R 5 and R 6 together represent C 2 -C 6 -alkylene chain,

provide that R 6 is not hydrogen when X is C.

3. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 1 , which is depicted by the following formula (1a):

in which

n, A, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in claim 1 .

4. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein R 1 represents hydrogen, C 1 -C 6 -alkyl or di(C 1 -C 3 -alkyl) amino-C 2 -C 3 -alkyl.

5. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 4 wherein R 1 represents hydrogen, methyl or (dimethylamino)ethyl.

6. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein R 2 represents hydrogen, amino, halogen, C 1 -C 3 -alkyl, carboxy, carboxy-C 1 -C 3 -alkyl, C 1 -C 3 -alkoxycarbonyl, C 1 -C 3 -alkoxycarbonyl-C 1 -C 3 -alkyl, hydroxy-C 1 -C 3 -alkyl, C 1 -C 3 -alkoxy, —(CH 2 ) p NR 7 R 8 , —NHR 10 , —N(H)S(O) 2 R 7 , —NHC(O)R 10 or —(CH 2 ) p -heterocycle-R 10 , wherein p, R 7 , R 8 and R 10 are as defined in claim 2 .

7. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 6 wherein R 2 is selected from the group consisting of hydrogen, methyl, methoxy, fluoro, —NH 2 , —NHAc, —NHSO 2 Me, —NHBOC, —NH(1-methyl-piperidine), 1-oxo-2-hydroxy-ethyl, dimethylaminomethyl, hydroxymethyl, hydroxyethyl, carboxy, carboxymethyl, carboxyethyl, —CH 2 -(2-oxo)piperazine, —CH 2 -piperazine, —CH 2 -morpholine, —CH 2 -[1,1-dioxo-thiomorpholin-4-yl], and —CH 2 [4-acetyl-piperazin-1-yl].

8. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein R 3 represents hydrogen, methyl or bromo, represents phenyl optionally substituted by C 1 -C 3 -alkoxy, or represents heterocyclyl-C 1 -C 3 -alkyl wherein the heterocycle is 5˜6 membered, has 1 or 2 hetero atoms selected from N and O, and is optionally substituted by 1 or 2 oxo groups.

9. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 8 wherein R 3 is selected from the group consisting of hydrogen, methyl, bromo, phenyl, 4-MeO-phenyl, —CH 2 -(2-oxo-piperazin-4-yl), and —CH 2 -(morpholin-4-yl).

10. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein Y is selected from the group consisting of a direct bond, —O—, —C(O)—, —NH—, —CONH—, —SO 2 NH—, —NHC(O)—, —CH 2 CONH—, —CH 2 C(O)—, and —CH 2 SO 2 —.

11. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 10 wherein Y is selected from the group consisting of a direct bond, —O—, —C(O)—, —CH 2 C(O)— and —NHC(O)—.

12. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein R 11 is selected from the group consisting of hydrogen, halogen, hydroxy, C 1 -C 6 -alkyl and —(CH 2 ) t B—R 13 wherein t, B and R 13 are as defined in claim 2 .

13. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 12 wherein R 11 is selected from the group consisting of hydrogen, methyl, ethyl, phenyl, fluoro, chloro, hydroxy, 2-carboxy-pyrrolidin-1-yl, pyrrolidin-1-yl, 4-acetic acid-1,3-thiazolin-2-yl, —CH 2 -(1,1-dioxo-thiomorpholin-4-yl), and —CH 2 -(2-oxopiperazin-4-yl).

14. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein R 5 represents hydrogen, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, heterocycle or heterocyclyl-C 1 -C 6 -alkyl, wherein the heterocycle is a 5˜6 membered ring which has 1 or 2 hetero atoms selected from N and O, and is optionally substituted by 1 or 2 oxo groups.

15. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 14 wherein R 5 is selected from the group consisting of hydrogen, methyl, cyclopentyl, tetrahydropyran-4-yl and CH 2 -(tetrahydropyran-4-yl).

16. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein Z represents a direct bond, or represents —C(O)—, —C(O)O—, —C(O)NH— or —S(O) 2 —.

17. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein D is selected from the group consisting of cyclopentyl, cyclohexyl, pyrrolidine, tetrahydropyran, tetrahydrofuran and piperidine.

18. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein W represents a direct bond, or represents —SO 2 —, —CO—, —C(O)O— or —CONR 12 —, wherein R 12 is as defined in claim 2 .

19. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 18 wherein W is selected from the group consisting of —SO 2 —, —CO—, —C(O)O—, —CON(Me)—, and —CONH—.

20. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein R 14 represents hydrogen, hydroxy, C 1 -C 6 -alkyl, hydroxy-C 1 -C 6 -alkyl, C 6 -C 10 -aryl or C 6 -C 10 -ar-C 1 -C 3 -alkyl, represents 5˜6 membered heterocycle which has O or S, and is optionally substituted by 1 or 2 oxo groups, or represents 5˜6 membered heteroaryl which has 1 or 2 hetero atoms selected from N, O and S, and is optionally substituted by C 1 -C 3 -alkyl.

21. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 20 wherein R 14 is selected from the group consisting of hydrogen, hydroxy, methyl, ethyl, isobutyl, hydroxymethyl, hydroxyethyl, phenyl, benzyl, thiophene, tetrahydrofuran, tetrahydropyran, 1,1-dioxo-tetrahydro-thiopyran, furan, pyridine and 5-methyl-pyridine.

22. The compound or pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof according to claim 2 wherein R 5 and R 6 together with the N atom to which they are attached form piperidine.

23. An indole or indazole compound, which is selected from the group consisting of:

Cyclopentyl-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]-amine;

Cyclopentyl-[5-methyl-2-phenyl-1H-indol-7-yl]-amine;

5-Chloro-2-(pyridin-2-yl)-1H-indol-7-yl]-amine;

(Tetrahydropyran-4-yl)-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

Cyclopentyl-[2-(pyrazin-2-yl)-1H-indol-7-yl]amine;

Cyclopentyl-[5-methyl-2-(pyrazin-2-yl)-1H-indol-7-yl]amine;

Cyclopentyl-[2-(pyridin-2-yl)-1H-indol-7-yl]amine;

(Tetrahydropyran-4-yl)-[2-(pyridin-2-yl)-1H-indol-7-yl]amine;

Cyclopentyl-[5-phenoxy-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

Cyclopentyl-[5-ethoxy-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

Cyclohexyl-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

1-[4-[(5-Methyl-2-(pyridin-2-yl)-1H-indol-7-yl)amino]piperidin-1-yl]ethanone;

(1-Methylpiperidin-4-yl)-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

(1-Benzylpyrrolidin-3-yl)-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

Cyclopentylmethyl-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

5-Methyl-(7-piperidin-1-yl)amino-2-(pyridin-2-yl)-1H-indole;

Dimethyl-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

Cyclopentyli1,5-dimethyl-2-(pyridin-2-yl)-indol-7-yl-amine;

Cyclopentyl-[5-methyl-2-(6-methylpyridin-2-yl)-1H-indol-7-yl]amine;

(1-Cyclohexanon-4-yl)-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

4-[(5-Chloro-2-phenyl-1H-indol-7-yl)amino]-cyclohexan-1-one;

N-(5-Methyl-2-(pyridin-2-yl)-1H-indol-7-yl)-benzamide;

1-Ethyl-3-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]urea;

1-Phenyl-3-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]urea;

Thiophene-2-sulfonic acid (2-pyridin-2-yl-1H-indol-7-yl)-amide;

Thiophene-2-sulfonic acid [5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]amide;

Cyclopentyl-methyl-[5-methyl-2-(pyridin-2-yl)-1H-indol-7-yl]amine;

7-(Cyclopentyl)amino-2-phenyl-1H-indole-5-carboxylic acid ethyl ester;

Cyclopentyl-[5-hydroxymethyl-2-phenyl-1H-indol-7-yl]-amine;

7-(Cyclopentyl)amino-2-phenyl-1H-indole-5-carboxylic acid;

2-[7-(Cyclopentyl)amino-2-phenyl-1H-indol-5-yl]-acetic acid ethyl ester;

2-[7-(Cyclopentylamino)-2-phenyl-1H-indol-5-yl]ethanol;

2-[7-(Cyclopentyl)amino-2-phenyl-1H-indol-5-yl]acetic acid;

2-[2-Phenyl-7-(tetrahydropyran-4-yl)amino-1H-indol-5-yl]acetic acid;

2-[2-Phenyl-7-(1,1-dioxo-tetrahydro-thiopyran-4-yl)amino-1H-indol-5-yl]acetic acid;

(Tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine;

(Tetrahydropyran-4-yl)-[2-phenyl-5-(2-oxo-piperazin-4-yl)methyl-1H-indol-7-yl]amine;

Cyclopentyl-[2-(3-fluoro)phenyl-5-(2-oxo-piperazin-4-yl)methyl-1H-indol-7-yl]amine;

(Tetrahydropyran-4-yl)-[2-(4-methoxy)phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine;

Cyclopentyl-[3,5-dimethyl-2-phenyl-1H-indol-7-yl]amine;

(Tetrahydropyran-4-yl)-(5-methyl-2-phenyl-1H-indol-7-yl)-amine;

Cyclopentylmethyl-(5-methyl-2-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-ylmethyl)-(5-methyl-2-phenyl-1H-indol-7-yl)-amine;

(1-Methylpiperidin-4-yl)-(5-methyl-2-phenyl-1H-indol-7-yl)-amine;

1-[-4-[(5-Methyl-2-phenyl-1H-indol-7-yl)amino]piperidin-1-yl]ethanone;

Cyclopentyl-(5-chloro-2-phenyl-1H-indol-7-yl)-amine;

Cyclohexyl-(5-chloro-2-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-yl)-(5-chloro-2-phenyl-1H-indol-7-yl)-amine;

Cyclopentylmethyl-(5-chloro-2-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-ylmethyl)-(5-chloro-2-phenyl-1H-indol-7-yl)-amine;

(1-Benzylpyrrolidin-3-yl)-(5-chloro-2-phenyl-1H-indol-7-yl)-amine;

(1-Methylpiperidin-4-yl)-(5-chloro-2-phenyl-1H-indol-7-yl)-amine;

(1,4-Dioxaspiro[4.5]decan-8-yl)-(5-chloro-2-phenyl-1H-indol-7-yl)-amine;

2-[(5-Chloro-2-phenyl-1H-indol-7-yl)amino]propan-1,3-diol;

(Tetrahydropyran-4-yl)-(5-methyl-2-phenyl-1H-indol-7-yl)-methyl-amine;

(Tetrahydropyran-4-ylmethyl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine;

Di(tetrahydropyran-4-ylmethyl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine;

Di(tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine;

(1-Methyl-piperidinemethyl-4-yl)-[5-fluoro-2-phenyl-1H-indol-7-yl]amine;

2-[4-[(5-Fluoro-2-phenyl-1H-indol-7-yl)amino]piperidin-1-yl]ethanol;

[1-(Tetrahydropyran-4-yl)piperidin-4-yl]-(5-fluoro-2-phenyl-1H-indol-7-yl)amine;

(Tetrahydropyran-4-yl)-(5-phenoxy-2-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-ylmethyl)-[2-phenyl-5-(2-oxo-piperazin-4-methyl-1H-indol-7-yl]amine;

(Tetrahydropyran-4-yl)-[5-chloro-1-(2-diethylaminoethyl)-2-phenyl-1H-indol-7-yl]amine;

Dimethyl-(5-chloro-1-methyl-2-phenyl-1H-indol-7-yl)amine;

(Tetrahydropyran-4-yl)-(5-chloro-1-methyl-2-phenyl-1H-indol-7-yl)-methylamine;

(Tetrahydropyran-4-yl)-(5-chloro-3-phenyl-1H-indol-7-yl)-amine;

Cyclopentyl-(5-chloro-3-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-ylmethyl)-(5-chloro-3-phenyl-1H-indol-7-yl)-amine;

Cyclopentyl-(5-chloro-3-(morpholin-4-yl)methyl-2-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-yl)-(5-chloro-3-(morpholin-4-yl)methyl-2-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-yl)-(5-chloro-3-(2-oxo-piperazin-4-yl)methyl-2-phenyl-1H-indol-7-yl)-amine;

Cyclopentyl-(5-chloro-3-(2-oxo-piperazin-4-yl)methyl-2-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-ylmethyl)-(5-chloro-3-(2-oxo-piperazin-4-yl)methyl-2-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-yl)-(3-bromo-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-2-phenyl-1H-indol-7-yl)-amine;

Cyclopentyl-(3-bromo-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-2-phenyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-ylmethyl)-(3-bromo-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-2-phenyl-1H-indol 1-7-yl)-amine;

(Tetrahydropyran-4-yl)-(5-(1,1-dioxo-thiomorpholin-4-yl)methyl-2-(3-fluorophenyl)-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-yl)-(5-chloro-3-phenyl-1H-indol-7-yl)-amine;

(3-Methylbutyl)-[5-(1,1-dioxo-thiomorpholin-4-yl)methyl-2-(4-methoxyphenyl)-1H-indol-7-yl]-amine;

t-Butyl N-[4-[5-chloro-7-(cyclopentylamino)-1H-indol-2-yl]phenyl]carbamate;

Cyclopentyl-[2-(4-aminophenyl)-5-chloro-1H-indol-7-yl]amine;

Cyclopentyl-{5-chloro-2-[4-(1-methyl-piperidin-4-yl)aminophenyl]-1H-indol-7-yl}-amine;

N-[4-(5-chloro-7-cyclopentylamino-1H-indol-2-yl)-phenyl]methanesulfonamide;

Cyclopentyl-{5-(1,1-dioxo-thiomorpholin-4-yl)methyl-2-[4-(acetyl)aminophenyl]-1H-indol-7-yl}-amine;

Dicyclopentyl-{5-(1,1-dioxo-thiomorpholin-4-yl)-2-[4-(acetyl)aminophenyl]-1H-indol-7-yl}-amine;

(Tetrahydropyran-4-yl)methyl-{5-(1,1-dioxo-thiomorpholin-4-yl)-2-[4-(acetyl)aminophenyl]-1H-indol -7-yl}-amine;

Di(tetrahydropyran-4-yl)methyl-{5-(1,1-dioxo-thiomorpholin-4-yl)-2-[4-(acetyl)aminophenyl]-1H-indol -7-yl}-amine;

(Tetrahydropyran-4-yl)-{5-(1,1-dioxo-thiomorpholin-4-yl)-2-[4-(acetyl)aminophenyl]-1H-indol-7-y1}-amine;

(5-Methyl-2-phenyl-1H-indol-7-yl)-piperidin-4-yl-amine;

[1-(Methanesulfonyl)piperidin-4-yl]-(5-methyl-2-phenyl-1H-indol-7-yl)-amine;

2-Hydroxy-1-[4-(5-methyl-2-phenyl-1H-indol-7-yl)amino-piperidin-1-yl]ethanone;

(5-Chloro-2-phenyl-1H-indol-7-yl)-piperidin-4-yl-amine;

4-(5-Chloro-2-phenyl-1H-indol-7-yl)amino-piperidin-1-yl-carboxylic acid phenylamide;

1-[4-(5-Chloro-2-phenyl-1H-indol-7-yl)amino-piperidin-1-yl]-2-dimethylamino-ethanone;

[5-(1,1-Dioxo-thiomorpholin-4-yl)methyl-2-phenyl-1H-indol-7-yl]-(piperidin-4-yl)methyl-amine;

(5-(1,1-Dioxo-thiomorpholin-4-yl)methyl-2-phenyl-1H-indol-7-yl)-(1-methanesulfonyl-piperidin-4- yl)-amine;

{4-[5-(1,1-Dioxo-thiomorpholin-4yl)methyl-2-phenyl-1H-indol-7-yl]amino-piperidin-1-yl}-(tetrahydrofuran-2-yl)-methanone;

(5-Fluoro-2-phenyl-1H-indol-7-yl)[1-(1,1-dioxo-tetrahydrothiopyran-4-yl)-piperidin-4-yl]-amine;

N-(5-Chloro-2-phenyl-1H-indol-7-yl)-N′,N′-dimethyl-cyclohexane-1,4-diamine;

N-(5-Chloro-2-phenyl-1H-indol-7-yl)-N′-methyl-cyclohexane-1,4-diamine;

4-(5-Chloro-2-phenyl-1H-indol-7-yl)amino-cyclohexane-1-carboxylic acid;

4-(5-Methyl-2-phenyl-1H-indol-7-yl)amino-cyclohexane-1-carboxylic acid;

4-(5-Chloro-2-phenyl-1H-indol-7-yl)amino-cyclohexane-1-carboxylic acid amide;

4-(5-Chloro-2-phenyl-1H-indol-7-yl)amino-cyclohexanecarboxylic acid methylamide;

2-(5-Fluoro-2-phenyl-1H-indol-7-yl)amino-acetic acid methyl ester;

2-(5-Fluoro-2-phenyl-1H-indol-7-yl)amino-acetic acid;

2-(5-Phenoxy-2-phenyl-1H-indol-7-yl)amino-acetic acid methyl ester;

2-[(5-Phenoxy-2-phenyl-1H-indol-7-yl)amino]-acetic acid;

2-[(5-Phenoxy-2-phenyl-1H-indol-7-yl)amino]-propionic acid methyl ester;

2-(5-Phenoxy-2-phenyl-1H-indol-7-yl)amino-propionic acid;

2-(5-Chloro-2-phenyl-1H-indol-7-yl)amino-propionic acid;

(5-Chloro-2-phenyl-1H-indol-7-yl)-pyridin-2-yl-amine;

(5-Chloro-2-phenyl-1H-indol-7-yl)-5-methyl-pyridin-2-yl-amine;

(5-Chloro-3-phenyl-1H-indol-7-yl)-(5-methyl-pyridin-2-yl)-amine;

(2S)-1-(7-cyclopentylamino-2-phenyl-1H-indole-5-carbonyl)-pyrrolidine-2-carboxylic acid methyl ester;

(2S)-1-(7-cyclopentylamino-2-phenyl-1H-indole-5-carbonyl)-pyrrolidine-2-carboxylic acid;

(2S)-1-[2-phenyl-7-(tetrahydropyran-4-yl)amino-1H-indole-5-carbonyl]-pyrrolidine-2-carboxylic acid;

2-(7-Cyclopentylamino-2-phenyl-1H-indol-5-yl]-1-pyrrolidin-1-yl-ethanone;

Cyclopentyl-[2-phenyl-5-(2-pyrrolidin-1-yl-ethyl)-1H-indol-7-yl]-amine;

2-[(R)-2-(7-cyclopentylamino-2-phenyl-1H-indol-5-yl)-4,5-dihydro-thiazol-4-yl]-acetic acid;

2-[(R)-2-(2-phenyl-7-(tetrahydropyran-4-yl)methylamino-1H-indol-5-yl)-4,5-dihydro-thiazol-4-yl]-acetic acid;

3-(7-Cyclopentylamino-5-chloro-1H-indol-2-yl)-benzoic acid methyl ester;

3-(7-Cyclopentylamino-5-chloro-1H-indol-2-yl)-benzoic acid;

[3-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)-phenyl]-methanol;

{3-[5-Chloro-7-(tetrahydropyran-4-yl)amino-1H-indol-2-yl]-phenyl}-methanol;

2-{3-[5-Chloro-7-(tetrahydropyran-4-ylmethyl)amino-1H-indol-2-yl]-phenyl}-acetic acid;

2-[3-(5-Chloro-7-cyclopentylamino-1-H-indol-2-yl)-phenyl]-acetic acid;

2-{3-[5-Chloro-7-(tetrahydropyran-4-yl)amino-1H-indol-2-yl]-phenyl}-acetic acid;

2-{3-[5-Chloro-7-(tetrahydropyran-4-ylmethyl)amino-1H-indol-2-yl]-phenyl}-acetic acid methyl ester;

2-[3-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)-phenyl]-acetic acid methyl ester;

2-{3-[5-Chloro-7-(tetrahydropyran-4-yl)amino)-1H-indol-2-yl]-phenyl}-acetic acid methyl ester;

[2-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)-phenyl]-methanol;

2-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)-benzoic acid;

2-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)-benzoic acid methyl ester;

[4-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)-phenyl]-methanol;

2-{4-[5-Chloro-7-(tetrahydropyran-4-yl)amino-1H-indol-2-yl]phenyl}-ethanol;

4-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)-benzoic acid;

2-{4-[5-Chloro-7-(tetrahydropyran-4-ylmethyl)amino-1H-indol-2-yl]phenyl}-acetic acid;

2-[4-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)phenyl]-acetic acid;

2-{4-[5-Chloro-7-(tetrahydropyran-4-yl)amino-1H-indol-2-yl]phenyl}-acetic acid;

4-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)benzoic acid methyl ester;

4-(7-Cyclopentylamino-5-methyl-1H-indol-2-yl)benzoic acid methyl ester;

2-{4-[5-Chloro-7-(tetrahydropyran-4-ylmethyl)amino-1H-indol-2-yl]phenyl}-acetic acid methyl ester;

2-[4-(5-Chloro-7-cyclopentylamino-1H-indol-2-yl)phenyl]acetic acid methyl ester;

2-{4-[5-Chloro-7-(tetrahydropyran-4-yl)amino-1H-indol-2-yl]phenyl}-acetic acid methyl ester;

[5-Chloro-2-(3-dimethylaminomethylphenyl)-1H-indol-7-yl]-(tetrahydropyran-4-yl)-amine;

[5-Chloro-2-(3-morpholin-4-ylmethylphenyl)-1H-indol-7-yl]-(tetrahydropyran-4-yl)-amine;

[5-Chloro-2-(3-pyrrolidin-4-ylmethylphenyl)-1H-indol-7-yl]-(tetrahydropyran-4-yl)-amine;

1-{4-[3-(5-Chloro-7-tetrahydropyran-4-ylamino-1H-indol-2-yl)-benzyl]-piperazin-1-yl}-ethanone;

{5-Chloro-2-[3-(2-oxo-piperazin-4-yl)ethylphenyl]-1H-indol-7-yl}-(tetrahydropyran-4-yl)-amine;

{5-Chloro-2-[3-(1,1-dioxo-thiomorpholin-4-yl)ethylphenyl]-1H-indol-7-yl}-(tetrahydropyran-4-yl)-amine ;

Cyclopentyl-(1H-indazol-7-yl)-amine;

(Tetrahydropyran-4-yl)-(1H-indazol-7-yl)-amine;

Cyclopentyl-(5-methyl-1H-indazol-7-yl)-amine;

(5-Methyl-1H-indazol-7-yl)-(tetrahydropyran-4-yl)-amine;

Cyclopentyl-[3-(4-methoxyphenyl)-1H-indazol-7-yl)-amine;

[3-(4-Methoxyphenyl)-1H-indazol-7-yl)]-(tetrahydropyran-4-yl)-amine;

[3-(4-Methoxyphenyl)-1H-indazol-7-yl)-(tetrahydropyran-4-ylmethyl)-amine;

(Tetrahydropyran-4-yl)-[5-(1,1-dioxo-thiomorpholin-4-yl)methyl-3-phenyl-2-trimethylsilyl-1H-indol-7-yl)-amine;

(Tetrahydropyran-4-yl)-[5-(1,1-dioxo-thiomorpholin-4-yl)methyl-3-phenyl-1H-indol-7-yl)-amine; and

(Tetrahydropyran-4-yl)-[3-bromo-5-(morpholin-4-yl)methyl-2-phenyl-1H-indol-7-yl]-amine, and pharmaceutically acceptable salts or stereoisomers or geometric isomers thereof.

24. A composition which comprises a therapeutically-effective amount of a compound or pharmaceutically acceptable salt or a stereoisomer or geometric isomer thereof according to claim 1 as an active ingredient together with a pharmaceutically acceptable carrier or diluent.